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BACKGROUND
Postpartum hemorrhage is the most common cause of maternal death. Oxytocin is 
the standard therapy for the prevention of postpartum hemorrhage, but it requires 
cold storage, which is not available in many countries. In a large trial, we compared 
a novel formulation of heat-stable carbetocin with oxytocin.
METHODS
We enrolled women across 23 sites in 10 countries in a randomized, double-blind, 
noninferiority trial comparing intramuscular injections of heat-stable carbetocin 
(at a dose of 100 μg) with oxytocin (at a dose of 10 IU) administered immediately 
after vaginal birth. Both drugs were kept in cold storage (2 to 8°C) to maintain 
double-blinding. There were two primary outcomes: the proportion of women with 
blood loss of at least 500 ml or the use of additional uterotonic agents, and the propor-
tion of women with blood loss of at least 1000 ml. The noninferiority margins for the 
relative risks of these outcomes were 1.16 and 1.23, respectively.
RESULTS
A total of 29,645 women underwent randomization. The frequency of blood loss of at 
least 500 ml or the use of additional uterotonic agents was 14.5% in the carbetocin 
group and 14.4% in the oxytocin group (relative risk, 1.01; 95% confidence interval 
[CI], 0.95 to 1.06), a finding that was consistent with noninferiority. The frequency 
of blood loss of at least 1000 ml was 1.51% in the carbetocin group and 1.45% in 
the oxytocin group (relative risk, 1.04; 95% CI, 0.87 to 1.25), with the confidence 
interval crossing the margin of noninferiority. The use of additional uterotonic 
agents, interventions to stop bleeding, and adverse effects did not differ significantly 
between the two groups.
CONCLUSIONS
Heat-stable carbetocin was noninferior to oxytocin for the prevention of blood 
loss of at least 500 ml or the use of additional uterotonic agents. Noninferiority 
was not shown for the outcome of blood loss of at least 1000 ml; low event rates 
for this outcome reduced the power of the trial. (Funded by Merck Sharpe & 
Dohme; CHAMPION Australian New Zealand Clinical Trials Registry number, 
ACTRN12614000870651; EudraCT number, 2014-004445-26; and Clinical Trials 
Registry–India number, CTRI/ 2016/ 05/ 006969.)
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Despite substantial reductions in maternal mortality, hemorrhage contin-ues to be the largest direct cause of ma-
ternal death, accounting for 661,000 deaths world-
wide between 2003 and 2009.1 More than 70% of 
hemorrhagic deaths occur post partum, and most 
are due to uterine atony, which results from poor 
contraction of the uterus after childbirth. Oxyto-
cin, the current standard therapy for the preven-
tion of postpartum hemorrhage, has unsatisfactory 
real-world efficacy as a result of sensitivity to heat 
and quality issues such as insufficient active in-
gredient or impurities.2,3 Heat-stable carbetocin, 
an oxytocin analogue, does not require cold-chain 
transport and storage; it has been shown to main-
tain stability over a period of 36 months at 30°C 
and 75% relative humidity.4 The heat-stable for-
mulation of carbetocin differs from the existing 
non–heat-stable formulation only in its excipients.
The World Health Organization (WHO) did not 
include a recommendation for carbetocin in its 
2012 guideline regarding postpartum hemorrhage.2 
Although there have been trials of carbetocin, 
most of the trials involved women undergoing ce-
sarean section, were small, were of varied quality, 
and used an intravenous route of administration.5
In 2013, the WHO was approached by Merck 
for Mothers (a philanthropic initiative of Merck, 
known outside the United States as Merck Sharpe 
& Dohme [MSD]) and Ferring Pharmaceuticals to 
explore the potential value of heat-stable carbetocin 
for reducing the incidence of maternal death. The 
WHO convened an international panel of stake-
holders who identified the need for demonstration 
of noninferiority of heat-stable carbetocin before a 
change in guidance and practice could be consid-
ered. If noninferior to oxytocin, the heat-stable 
formulation of carbetocin would be made available 
in public-sector facilities of high-burden countries 
at an affordable and sustainable price, according to 
a memorandum of understanding signed by rep-
resentatives of the WHO, Ferring Pharmaceuti-
cals, and Merck. We thus performed a noninfe-
riority trial comparing the effects of heat-stable 
carbetocin with those of oxytocin on postpartum 
hemorrhage after vaginal birth.
Me thods
Trial Design and Oversight
We conducted an international, randomized, dou-
ble-blind, active-controlled, noninferiority trial 
comparing heat-stable carbetocin with oxytocin 
for the prevention of postpartum hemorrhage dur-
ing the third stage of labor in women giving birth 
vaginally at 23 hospitals (sites) in 10 countries — 
Argentina, Egypt, India, Kenya, Nigeria, Singapore, 
South Africa, Thailand, Uganda, and the United 
Kingdom — between July 7, 2015, and January 30, 
2018. The trial protocol (available with the full 
text of this article at NEJM.org) has been published 
previously.6 The trial protocol was approved by the 
relevant ethics committees and regulatory agencies 
in each country, by the research proposals review 
panel of the Special Program of Research in Hu-
man Reproduction (HRP) that is based at the 
WHO, and by the WHO Ethics Review Committee.
HRP oversaw the conduct of the trial, which 
was performed in accordance with Good Clinical 
Practice guidelines.7 An external data and safety 
monitoring committee provided independent over-
sight and reviewed two interim analyses: the first 
analysis was to evaluate safety when 5000 partici-
pants had been recruited, and the second was to 
evaluate safety and efficacy when 15,000 partici-
pants had been recruited. The interim analyses 
were blinded to everyone except the members of 
the data and safety monitoring committee. On 
both occasions, the data and safety monitoring 
committee recommended continuation of the trial.
Trial initiation, monitoring, and closure and 
safety monitoring at the trial sites were provided 
by IQVIA (formerly Quintiles IMS–Quintiles). Cen-
tro Rosarino de Estudios Perinatales in Rosario, 
Argentina, provided assistance with data manage-
ment, including preparation of the trial online 
data-entry system, electronic case-record forms, 
and data monitoring and cleaning. Statistika Con-
sultoria in Campinas, Brazil, provided statistical 
assistance. The trial protocol, statistical analysis 
plan, and the manuscript were written by HRP 
staff, the trial statistician, independent steering 
committee members who were not WHO staff or 
site investigators, and the site principal investi-
gators.
The trial was supported by MSD, through the 
MSD for Mothers Program, an initiative of Merck; 
MSD had no commercial interest in the investiga-
tional drug. Heat-stable carbetocin was provided 
by Ferring Pharmaceuticals and oxytocin by Novar-
tis free of charge. Novartis had no other role in 
the trial. MSD and Ferring Pharmaceuticals pro-
vided input into the protocol and could provide 
comments on the manuscript, although there was 
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no obligation on the part of the team to incor-
porate them. No company had the right to final 
approval of the manuscript or to control the deci-
sion to submit the manuscript for publication. 
The authors vouch for the accuracy and complete-
ness of the data and analyses and for the fidelity 
of this report to the to the protocol.
Trial Participants and Interventions
Women who expected to give birth vaginally and 
who had a singleton pregnancy and cervical dila-
tation of 6 cm or less were eligible. Women were 
not eligible if they were in an advanced stage of 
labor (cervical dilatation >6 cm); were too dis-
tressed to provide informed consent; had known 
allergies to carbetocin, oxytocin homologues, or 
excipients; or had a serious cardiovascular disor-
der, serious hepatic or renal disease, or epilepsy. 
All the participants provided written informed 
consent.
Women underwent randomization when vagi-
nal birth was imminent. Women were randomly 
assigned to receive a single intramuscular injec-
tion of either heat-stable carbetocin at a dose of 
100 μg or oxytocin at a dose of 10 IU. Immedi-
ately after the birth of the baby, the drug was ad-
ministered and the management of the third stage 
of labor was conducted as recommended in the 
WHO guidelines.2 Once the umbilical cord was 
clamped and cut, a plastic drape for blood collec-
tion (BRASSS-V Drape) was placed under the 
woman’s buttocks. Blood was collected for 1 hour 
or for 2 hours if the bleeding continued beyond 
1 hour. The drape with the blood was then weighed 
by a digital scale, with the weight recorded in grams 
and then converted to volume (milliliters) after 
the weight of the drape was subtracted at the 
analysis stage.8
Participation in the trial ended at discharge 
from the facility, transfer of the woman to a 
higher care unit, or death. Information on serious 
and other adverse events was collected from the 
time of informed consent until the event resolved.
Heat-stable carbetocin and oxytocin were both 
supplied in 1-ml ampules in consecutively num-
bered treatment packs that were arranged in dis-
pensers. The ampules, trial packs, and dispensers 
were identical in shape, size, and weight to en-
sure that investigators were unaware of the indi-
vidual treatment assignments. Although carbe-
tocin was heat stable and did not require cold 
storage, the dispensers were kept in cold storage 
(2 to 8°C) to give oxytocin maximum efficacy and 
to maintain double-blinding.
The random-assignment sequence was gener-
ated at the WHO with the use of computer-gener-
ated random numbers. Randomization was strati-
fied according to country with the use of permuted 
blocks of 10, with an assignment ratio of 1:1. As-
signment was performed by opening the consecu-
tively numbered treatment pack in the dispenser.
Primary and Secondary Outcomes
There were two primary outcomes. The first was 
a composite outcome of the proportion of women 
with blood loss of at least 500 ml or the use of 
additional uterotonic agents at 1 hour and up to 
2 hours for women who continued to bleed after 
1 hour. This outcome was deemed to be sufficient 
and appropriate for submission for regulatory ap-
proval after discussion with the U.K. Medicines 
and Healthcare Products Regulatory Agency. The 
second primary outcome was the proportion of 
women with blood loss of at least 1000 ml at 
1 hour and up to 2 hours for women who contin-
ued to bleed after 1 hour. This outcome had been 
used in earlier WHO guidelines regarding the 
prevention of postpartum hemorrhage. For these 
two primary outcomes, a noninferiority hypoth-
esis was used.
Secondary outcomes included other measure-
ments related to blood loss, such as the use of 
additional uterotonic agents, other interventions 
to stop bleeding (Table S1 in the Supplementary 
Appendix, available at NEJM.org), and expected 
adverse effects, including chest pain, flushing, ab-
dominal pain, and vomiting. For secondary out-
comes, a superiority hypothesis was used.
Statistical Analysis
Details of the statistical analysis have been pub-
lished previously6 and are available with the trial 
protocol. For the primary outcome of blood loss 
of at least 500 ml or the use of additional utero-
tonic agents, we set a noninferiority margin of 
1.16 on the relative scale to preserve at least 82% 
of the effect of oxytocin over placebo, assuming 
the prevalences from a systematic review (15 to 
20% with oxytocin and 29 to 37% with placebo).9 
For the primary outcome of blood loss of at least 
1000 ml, we set the noninferiority margin to pre-
serve at least 75% of the effect of oxytocin over 
placebo, assuming a prevalence of this outcome 
of 2% with oxytocin10 and 3.84% with placebo 
The New England Journal of Medicine 
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(derived from rates with expectant management 
in a systematic review).11 Preserving 75% of 1.84 
percentage points (i.e., 3.84% − 2%) gave a margin 
on the absolute scale of 0.46 percentage points 
(or 2.46 ÷ 2 = 1.23 on the relative scale), assuming 
a 2% prevalence with oxytocin.
To show the noninferiority of heat-stable car-
betocin as compared with oxytocin within a mar-
gin of 1.23 on the relative scale, with 80% power 
and at a significance level of 2.5%, we calculated 
that 29,082 women would need to be enrolled, 
assuming an equal prevalence of blood loss of at 
least 1000 ml of 2% in each treatment group. We 
assumed a 3% rate of loss to follow-up, which 
resulted in an estimated sample size of 30,000. 
This sample size provided the trial with more than 
Figure 1. Trial Profile and Modified Intention-to-Treat and Per-Protocol Populations.
Informed consent was sought at hospital admission (see the protocol).
29,645 Underwent randomization
(intention-to-treat population)
34,165 Patients were assessed for eligibility
4520 Were excluded
34 Were not eligible
4483 Were found to be not eligible between
screening-form filing and delivery
3 Were eligible but did not undergo
randomization
14,823 Were assigned to receive
carbetocin
14,822 Were assigned to receive
oxytocin
2 Withdrew consent
3 Had consent form missing 
from source documents
47 Underwent cesarean section
14,771 Were included in the modified
intention-to-treat population
14,755 Were analyzed for end point
of blood loss of ≥500 ml
or additional uterotonics
(16 with missing data)
14,737 Were analyzed for end point
of blood loss of ≥1000 ml
(34 with missing data)
14,768 Were included in the modified
intention-to-treat population
14,752 Were analyzed for end point
of blood loss of ≥500 ml
or additional uterotonics
(16 with missing data)
14,733 Were analyzed for end point
of blood loss of ≥1000 ml
(35 with missing data)
2 Withdrew consent
4 Had consent form missing 
from source documents
48 Underwent cesarean section
19 Did not receive treatment
85 Had treatment administered
>3 min after birth of baby
25 Did not receive treatment
53 Had treatment administered
>3 min after birth of baby
14,667 Were included in the per-protocol
population
14,658 Were analyzed for end point
of blood loss of ≥500 ml
or additional uterotonics
(9 with missing data)
14,651 Were analyzed for end point
of blood loss of ≥1000 ml
(16 with missing data)
14,690 Were included in the per-protocol
population
14,685 Were analyzed for end point
of blood loss of ≥500 ml
or additional uterotonics
(5 with missing data)
14,677 Were analyzed for end point
of blood loss of ≥1000 ml
(13 with missing data)
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99% power for the outcome of blood loss of at least 
500 ml or the use of additional uterotonic agents. 
The sample size was calculated for different sce-
narios as specified in the protocol. For the sce-
nario of a prevalence of 1.5% for the outcome of 
blood loss of at least 1000 ml, the margin on the 
relative scale was 1.31. We defined a priori the 
number needed to harm (i.e., the number of 
women who would need to be treated with carbe-
tocin instead of oxytocin to result in one woman 
with blood loss of ≥1000 ml) for noninferiority 
as an absolute measure and stated that noninfe-
riority would be shown if the number needed to 
harm was 217 or more.
We present the primary-outcome results with 
adjustment for multiple comparisons as a com-
plementary analysis. However, our conclusions 
are based on the unadjusted results.
Analyses were planned according to the mod-
ified intention-to-treat and per-protocol popula-
tions. The modified intention-to-treat population 
included all the participants who underwent ran-
domization except those who withdrew consent, 
those whose consent form was missing from 
source documents, and those who underwent ce-
sarean section. The per-protocol population in-
cluded all the participants who received the as-
signed treatment within 3 minutes after delivery. 
To conclude that heat-stable carbetocin was non-
inferior to oxytocin, we required that noninferi-
ority be shown in both the modified intention-to-
treat and per-protocol analyses.
We used the Mantel–Haenszel method to cal-
culate summary relative-risk estimates and com-
mon risk (proportion) differences for tables of the 
type country by trial group by binary outcome. 
The confidence intervals were obtained by the Wald 
method, and the P value was from the Mantel–
Haenszel general association statistic. This ap-
proach differed from the modeling approach with 
the use of logistic regression as planned in the 
protocol, because the results from logistic regres-
sion were not reliable with scarce data. Missing 
values were not imputed. We planned to use com-
Characteristic
Carbetocin 
(N = 14,771)
Oxytocin 
(N = 14,768)
Age — yr
Median 25 25
Interquartile range 22–30 22–30
Nulliparous — no. (%) 6,424 (43.5) 6,457 (43.7)
Gestational age — wk
Median 39 39
Interquartile range 38–40 38–40
Labor induced — no. (%) 2,064 (14.0) 2,032 (13.8)
Labor augmented — no. (%) 6,891 (46.7) 6,948 (47.0)
Instrument‑assisted vaginal birth — no. (%) 568 (3.8) 580 (3.9)
Perineal trauma leading to suture — no. (%) 9,207 (62.3) 9,243 (62.6)
Birth weight — g
Median 3090 3080
Interquartile range 2780–3420 2800–3400
Baby alive — no. (%) 14,581 (98.7) 14,584 (98.8)
Previous cesarean section — no./total no. (%) 433/8347 (5.2) 459/8311 (5.5)
Previous postpartum hemorrhage — no./total no. (%) 121/8347 (1.4) 128/8311 (1.5)
*  The modified intention‑to‑treat population included all the participants who underwent randomization except those 
who withdrew consent, underwent cesarean section, or had another reason for withdrawal. Data regarding whether  
labor was induced or augmented or whether there was perineal trauma leading to suture were missing for one woman 
in the carbetocin group. There were no significant (P<0.05) differences between the two groups.
Table 1. Characteristics of Women at Trial Entry and of Women and Babies at Birth (Modified Intention-to-Treat 
Population).*
The New England Journal of Medicine 
Downloaded from nejm.org at WORLD HEALTH ORGANIZATION on June 27, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 6
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Ta
bl
e 
2.
 P
ri
m
ar
y 
an
d 
Se
co
nd
ar
y 
O
ut
co
m
es
.*
O
ut
co
m
e
C
ar
be
to
ci
n 
(N
 =
 1
4,
77
1)
O
xy
to
ci
n 
(N
 =
 1
4,
76
8)
R
el
at
iv
e 
R
is
k 
(9
5%
 C
I)
R
is
k 
D
iff
er
en
ce
 (
95
%
 C
I)
nu
m
be
r (
pe
rc
en
t)
pe
rc
en
ta
ge
 p
oi
nt
s
Pr
im
ar
y 
ou
tc
om
es
 in
 th
e 
m
od
ifi
ed
 in
te
nt
io
n-
to
-t
re
at
 p
op
ul
at
io
n
B
lo
od
 lo
ss
 ≥
50
0 
m
l o
r 
us
e 
of
 a
dd
iti
on
al
 u
te
ro
to
ni
c 
ag
en
ts
†
21
35
 (
14
.5
)
21
22
 (
14
.4
)
1.
01
 (
0.
95
 to
 1
.0
6)
0.
09
 (
−0
.6
8 
to
 0
.8
7)
B
lo
od
 lo
ss
 ≥
10
00
 m
l‡
22
3 
(1
.5
1)
21
4 
(1
.4
5)
1.
04
 (
0.
87
 to
 1
.2
5)
0.
06
 (
−0
.2
1 
to
 0
.3
3)
Pr
im
ar
y 
ou
tc
om
es
 in
 th
e 
pe
r-
pr
ot
oc
ol
 p
op
ul
at
io
n
N
o.
 o
f w
om
en
14
,6
67
14
,6
90
B
lo
od
 lo
ss
 ≥
50
0 
m
l o
r 
us
e 
of
 a
dd
iti
on
al
 u
te
ro
to
ni
c 
ag
en
ts
†
21
07
 (
14
.4
)
20
98
 (
14
.3
)
1.
01
 (
0.
96
 to
 1
.0
6)
0.
12
 (
−0
.6
6 
to
 0
.9
0)
B
lo
od
 lo
ss
 ≥
10
00
 m
l‡
22
2 
(1
.5
)
21
2 
(1
.4
)
1.
05
 (
0.
88
 to
 1
.2
7)
0.
08
 (
−0
.2
0 
to
 0
.3
5)
M
at
er
na
l s
ec
on
da
ry
 o
ut
co
m
es
 in
 th
e 
m
od
ifi
ed
 in
te
nt
io
n-
to
-t
re
at
 p
op
ul
at
io
n
B
lo
od
 lo
ss
 ≥
50
0 
m
l§
13
27
 (
9.
0)
13
43
 (
9.
1)
0.
99
 (
0.
92
 to
 1
.0
6)
—
U
se
 o
f a
dd
iti
on
al
 u
te
ro
to
ni
c 
ag
en
ts
 u
nt
il 
2 
hr
¶
13
39
 (
9.
1)
13
04
 (
8.
8)
1.
03
 (
0.
96
 to
 1
.1
0)
—
U
se
 o
f a
dd
iti
on
al
 u
te
ro
to
ni
c 
ag
en
ts
‖
15
33
 (
10
.4
)
15
28
 (
10
.4
)
1.
00
 (
0.
94
 to
 1
.0
7)
—
B
lo
od
 tr
an
sf
us
io
n
22
9 
(1
.6
)
19
8 
(1
.3
)
1.
16
 (
0.
96
 to
 1
.4
)
—
M
an
ua
l r
em
ov
al
 o
f p
la
ce
nt
a
79
 (
0.
5)
95
 (
0.
6)
0.
83
 (
0.
62
 to
 1
.1
2)
—
A
dd
iti
on
al
 s
ur
gi
ca
l p
ro
ce
du
re
s*
*
15
9 
(1
.1
)
13
8 
(0
.9
)
1.
15
 (
0.
92
 to
 1
.4
4)
—
M
at
er
na
l d
ea
th
4 
(<
0.
1)
2 
(<
0.
1)
2.
00
 (
0.
37
 to
 1
0.
92
)
—
M
at
er
na
l d
ea
th
 o
r 
se
ve
re
 c
om
pl
ic
at
io
n†
†
26
 (
0.
2)
23
 (
0.
2)
1.
13
 (
0.
65
 to
 1
.9
8)
—
N
ew
bo
rn
 s
ec
on
da
ry
 o
ut
co
m
es
 in
 th
e 
m
od
ifi
ed
 in
te
nt
io
n-
to
-t
re
at
 p
op
ul
at
io
n
N
o.
 o
f l
iv
e 
bi
rt
hs
14
,5
81
14
,5
84
N
ew
bo
rn
 d
ea
th
‡
‡
49
 (
0.
3)
47
 (
0.
3)
1.
04
 (
0.
7 
to
 1
.5
5)
—
A
pg
ar
 s
co
re
 <
7 
at
 5
 m
in
21
8 
(1
.5
)
22
9 
(1
.6
)
0.
95
 (
0.
79
 to
 1
.1
4)
—
N
ew
bo
rn
 r
es
us
ci
ta
tio
n
81
2 
(5
.6
)
81
2 
(5
.6
)
1.
00
 (
0.
91
 to
 1
.1
0)
—
M
ec
ha
ni
ca
l v
en
til
at
io
n
17
2 
(1
.2
)
16
4 
(1
.1
)
1.
05
 (
0.
85
 to
 1
.3
0)
—
* 
 Th
e 
m
od
ifi
ed
 in
te
nt
io
n‑
to
‑t
re
at
 p
op
ul
at
io
n 
in
cl
ud
ed
 a
ll 
th
e 
pa
rt
ic
ip
an
ts
 w
ho
 u
nd
er
w
en
t 
ra
nd
om
iz
at
io
n 
ex
ce
pt
 t
ho
se
 w
ho
 w
ith
dr
ew
 c
on
se
nt
, t
ho
se
 w
ho
se
 c
on
se
nt
 fo
rm
 w
as
 m
is
si
ng
 
fr
om
 t
he
 s
ou
rc
e 
do
cu
m
en
ts
, a
nd
 t
ho
se
 w
ho
 u
nd
er
w
en
t 
ce
sa
re
an
 s
ec
tio
n.
 T
he
 p
er
‑p
ro
to
co
l p
op
ul
at
io
n 
in
cl
ud
ed
 a
ll 
th
e 
pa
rt
ic
ip
an
ts
 w
ho
 r
ec
ei
ve
d 
th
e 
as
si
gn
ed
 t
re
at
m
en
t 
w
ith
in
 3
 m
in
‑
ut
es
 a
ft
er
 d
el
iv
er
y.
 A
na
ly
se
s 
w
er
e 
ba
se
d 
on
 a
va
ila
bl
e 
ou
tc
om
e 
da
ta
. M
is
si
ng
 v
al
ue
s 
w
er
e 
no
t 
in
cl
ud
ed
 in
 t
he
 c
al
cu
la
tio
ns
, a
nd
 t
he
 d
en
om
in
at
or
 e
xc
lu
de
s 
m
is
si
ng
 v
al
ue
s.
 T
he
 r
el
at
iv
e 
ri
sk
s 
ar
e 
fo
r 
th
e 
co
m
pa
ri
so
n 
of
 h
ea
t‑
st
ab
le
 c
ar
be
to
ci
n 
w
ith
 o
xy
to
ci
n.
 C
on
fid
en
ce
 in
te
rv
al
s 
w
er
e 
no
t 
ad
ju
st
ed
 fo
r 
m
ul
tip
le
 c
om
pa
ri
so
ns
. A
ll 
th
e 
P 
va
lu
es
 t
ha
t 
w
er
e 
ad
ju
st
ed
 fo
r 
m
ul
tip
le
 
co
m
pa
ri
so
ns
 fo
r 
th
e 
se
co
nd
ar
y 
ou
tc
om
es
, w
ith
 t
he
 u
se
 o
f t
he
 fa
ls
e‑
di
sc
ov
er
y‑
ra
te
 a
pp
ro
ac
h,
 w
er
e 
gr
ea
te
r 
th
an
 0
.9
0.
†
 
 Th
is
 o
ut
co
m
e 
w
as
 d
ef
in
ed
 a
s 
bl
oo
d 
lo
ss
 o
f a
t 
le
as
t 
50
0 
m
l o
r 
th
e 
us
e 
of
 a
dd
iti
on
al
 u
te
ro
to
ni
c 
ag
en
ts
 a
t 
1 
ho
ur
 a
nd
 u
p 
to
 2
 h
ou
rs
 in
 w
om
en
 w
ho
 c
on
tin
ue
d 
to
 b
le
ed
 a
ft
er
 1
 h
ou
r.
 I
n 
th
e 
m
od
ifi
ed
 in
te
nt
io
n‑
to
‑t
re
at
 p
op
ul
at
io
n,
 d
at
a 
w
er
e 
m
is
si
ng
 fo
r 
32
 w
om
en
 (
16
 in
 e
ac
h 
gr
ou
p)
. P
 =
 0
.8
1 
fo
r 
su
pe
ri
or
ity
 in
 t
he
 m
od
ifi
ed
 in
te
nt
io
n‑
to
‑t
re
at
 p
op
ul
at
io
n.
 I
n 
th
e 
pe
r‑
pr
ot
oc
ol
 
po
pu
la
tio
n,
 d
at
a 
w
er
e 
m
is
si
ng
 fo
r 
14
 w
om
en
 (
9 
in
 t
he
 c
ar
be
to
ci
n 
gr
ou
p 
an
d 
5 
in
 t
he
 o
xy
to
ci
n 
gr
ou
p)
. P
 =
 0
.7
6 
fo
r 
su
pe
ri
or
ity
 in
 t
he
 p
er
‑p
ro
to
co
l p
op
ul
at
io
n.
The New England Journal of Medicine 
Downloaded from nejm.org at WORLD HEALTH ORGANIZATION on June 27, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 7
Carbetocin to Prevent Hemorrhage after Vaginal Birth
plete-case analysis because missing values for pri-
mary outcomes were expected to be very few and 
balanced between groups. As a complementary 
analysis, a log-normal distribution was fitted to 
the blood-loss data, and the estimated probabil-
ities of blood loss of at least 500 ml and of at 
least 1000 ml were compared between treatments 
with the use of relative risk and the bootstrap 
technique to obtain confidence intervals for the 
relative risk. Because this parametric method used 
all the blood-loss data (instead of dichotomizing), 
it was expected to improve efficiency in terms of 
the precision of the estimates (see the Supple-
mentary Appendix).
The secondary outcomes were assessed only 
for superiority, with the use of relative risks with 
95% confidence intervals that were estimated with 
the same techniques as described for the primary 
outcomes. Because the statistical analysis plan did 
not include a provision for correcting the confi-
dence intervals for multiple comparisons, the 
widths of the confidence intervals were not ad-
justed for multiple comparisons, so the intervals 
should not be used to infer definitive treatment 
effects for secondary outcomes. Analyses were 
performed with SAS software, version 9.4 (SAS 
Institute), and JMP 13Pro software (JMP).
R esult s
Participants
We recruited 29,645 women in 10 countries. The 
trial profile and populations are shown in Fig-
ure 1. Cesarean birth after randomization occurred 
in 47 women (0.3%) in the carbetocin group and 
in 48 (0.3%) in the oxytocin group. Outcomes were 
missing for the first primary outcome for 16 par-
ticipants in each group and for the second pri-
mary outcome for 34 participants (0.2%) in the 
carbetocin group and for 35 (0.2%) in the oxytocin 
group. The characteristics at baseline and the birth 
outcomes were similar in the two groups (Table 1).
Primary Outcomes
The primary outcome of blood loss of at least 
500 ml or the use of additional uterotonic agents 
occurred in 14.5% of the women in the carbeto-
cin group and in 14.4% of those in the oxytocin 
group (relative risk, 1.01; 95% confidence inter-
val [CI], 0.95 to 1.06; 95% CI adjusted for mul-
tiple comparisons owing to having two primary 
outcomes, 0.94 to 1.07; P<0.001 for noninferior-‡ 
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ity), a result that was consistent with noninferi-
ority at the prespecified margin of 1.16. Superior-
ity was not shown (P = 0.81).
The second primary outcome, blood loss of at 
least 1000 ml, occurred in 1.51% of the women 
in the carbetocin group and in 1.45% of those in 
the oxytocin group (relative risk, 1.04; 95% CI, 
0.87 to 1.25; adjusted 95% CI, 0.85 to 1.28; P = 0.03 
for noninferiority). The nonsignificant results for 
the second primary outcome were close to show-
ing noninferiority but did not, probably owing to 
lack of power.12 On the absolute scale, the upper 
limit of the 95% confidence interval for the risk 
difference was 0.33 percentage points (Table 2), 
which was below the prespecified margin of 0.46 
percentage points, and the corresponding num-
ber needed to harm was 303 (100 ÷ 0.33), which 
was higher than the preset value of 217 (100 ÷ 0.46) 
for indicating noninferiority.
In analyses fitting a log-normal distribution, 
followed by bootstrap techniques to obtain con-
fidence intervals for the relative risk, the relative 
risk for the outcome of blood loss of at least 
1000 ml that was associated with heat-stable 
carbetocin, as compared with oxytocin, was 1.00 
(95% CI, 0.89 to 1.13), which was within the non-
inferiority margin of 1.23. We also performed a 
post hoc analysis using a composite outcome of 
blood loss of at least 1000 ml or the use of ad-
ditional uterotonic agents; the relative risk was 
1.01 (95% CI, 0.95 to 1.09).
Results in the modified intention-to-treat and 
per-protocol populations did not differ materially 
from each other. In the per-protocol population, 
results for the outcome of blood loss of at least 
500 ml or the use of additional uterotonic agents 
were consistent with the noninferiority of carbe-
tocin (relative risk vs. oxytocin, 1.01; 95% CI, 0.96 
to 1.06). For the outcome of blood loss of at least 
1000 ml, the upper limit of the 95% confidence 
interval (1.27) was above the noninferiority mar-
gin of 1.23 (Table 2).
Secondary Outcomes and Adverse Effects
There were no differences at the 5% level of sig-
nificance between groups in the rates of the sec-
ondary outcomes (Table 2). There were six mater-
nal deaths (four in the carbetocin group and two 
in the oxytocin group). In the carbetocin group, 
deaths were due to uterine atony, retained placenta 
with hemorrhage, sepsis, and placental abruption 
causing intrapartum and postpartum hemorrhage 
(in one participant each). In the oxytocin group, 
deaths were due to amniotic fluid embolism and 
to placental abruption causing intrapartum and 
postpartum hemorrhage (in one participant each). 
Among the women who received treatment (safety 
population), the frequencies of the expected ad-
verse effects did not differ significantly between 
the two groups (Table 3).
In the safety population, the percentages of 
women with at least one unanticipated adverse 
event were 4.9% in the carbetocin group and 4.7% 
in the oxytocin group. The percentages of women 
who had at least one serious adverse event were 
0.7% in the carbetocin group and 0.6% in the oxy-
tocin group.
Discussion
In this multicenter, double-blind, randomized trial, 
we found that the intramuscular administration of 
100 μg of heat-stable carbetocin was noninferior 
to the administration of 10 IU of oxytocin for 
the prevention of postpartum hemorrhage after 
vaginal birth, when the outcome was defined as 
blood loss of at least 500 ml or the use of addi-
tional uterotonic agents. For the second primary 
outcome of blood loss of at least 1000 ml, non-
inferiority was not shown; the upper 95% confi-
dence limit exceeded the noninferiority margin.
We calculated our sample size on the basis of 
literature describing a prevalence of 2% of blood 
loss of at least 1000 ml.10 However, in our trial, 
this outcome occurred in 1.51% of the participants 
in the carbetocin group and in 1.45% of those in 
the oxytocin group. Despite the fact that this 
was a very large, randomized trial investigating 
the prevention of postpartum hemorrhage, it was 
underpowered for the outcome of blood loss of at 
least 1000 ml. In contrast to our primary pre-
specified noninferiority analysis for this outcome, 
the log-normal analysis, which had the advantage 
of taking into account all the blood-loss measures 
instead of dichotomizing them, provided narrower 
95% confidence intervals that were entirely within 
the prespecified noninferiority margin of 1.23. We 
found no significant differences between the two 
groups with regard to secondary outcomes or ad-
verse effects.
The present trial provides a large-scale noninfe-
riority evaluation of heat-stable carbetocin against 
oxytocin as the standard therapy. Previous studies 
have been small, with likely biases and differences 
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in doses, administration routes, and study popu-
lations. Five previous trials compared carbetocin 
with oxytocin.5 Four of these trials involved women 
with cesarean births only, and the oxytocin doses 
that were used ranged from an intravenous bolus 
of 2.5 IU or 5 IU to the infusion of 10 IU over a 
period of 2 hours. These trials were not designed 
as noninferiority trials.
The trial was motivated by the proven heat-sta-
bility profile of heat-stable carbetocin.4 Although 
the United Nations Commission for Life-Saving 
Commodities recommends that oxytocin be sup-
plied and stored between 2°C and 8°C to ensure 
efficacy,13 in many settings oxytocin is still stored 
at room temperature, which leads to degradation 
and loss of efficacy in approximately one third 
of ampules.3 In the present trial, we used high-
quality oxytocin and stored both the heat-stable 
carbetocin and the oxytocin between 2°C and 
8°C to maintain blinding and to provide oxytocin 
the best chance of efficacy. Thus, the present trial 
may underestimate the benefit that would be ex-
pected with the use of heat-stable carbetocin in 
low-income and middle-income countries. Avoid-
ing the need for a cold chain will enable lower-
cost transport and storage as well as reduce the 
waste associated with heat-exposure–related deg-
radation and loss of active ingredient. Within the 
labor-ward environment, eliminating a need for 
cold storage will facilitate easier access to the drug 
for patient care.
In conclusion, this multicenter trial showed 
the noninferiority of heat-stable carbetocin, as 
compared with oxytocin, for the primary outcome 
of blood loss of at least 500 ml or the use of ad-
ditional uterotonic agents. Noninferiority was not 
shown for the primary outcome of blood loss of 
at least 1000 ml; however, the trial was under-
powered for this outcome. There were no signifi-
cant differences between the two groups in other 
measures of bleeding or in adverse effects. These 
data inform care of women in parts of the world 
where a lack of heat stability is a barrier to the ef-
fective prevention of postpartum hemorrhage.
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Side Effect
Carbetocin 
(N = 14,754)
Oxytocin 
(N = 14,743)
Risk Difference 
(95% CI)
no. of women with event (%) percentage points
Chest pain 13 (0.09) 6 (0.04) 0.05 (−0.01 to 0.11)
Flushing 5 (0.03) 4 (0.03) 0.01 (−0.03 to 0.05)
Abdominal pain 63 (0.43) 56 (0.38) 0.05 (−0.10 to 0.19)
Vomiting 33 (0.22) 27 (0.18) 0.04 (−0.06 to 0.14)
*  The safety population included all the participants who received treatment. 
The risk difference was adjusted for country.
Table 3. Side Effects in the Safety Population.*
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